Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Astria Therapeutics, Inc. (NASDAQ:ATXS) reported financial results for Q1 2024, highlighting the positive proof-of-concept results of STAR-0215 for HAE treatment. The company plans to start Phase 3 trials in Q1 2025 and expand label with Q6M administration. Moreover, Astria is developing STAR-0310 for atopic dermatitis and aims to submit an IND application by 2024. The company also shared corporate updates and financial results.
Positive results from ALPHA-STAR trial for STAR-0215 in HAE treatment, showing a reduction in attack rates and positive safety profile.
Plans to initiate Phase 3 trial for STAR-0215 in Q1 2025 and expand label with Q6M administration to reduce treatment burden for HAE patients.
Development of STAR-0310 for atopic dermatitis, potentially having the best-in-class profile in AD.
Appointment of Dr. Sunil Agarwal to the Board of Directors, bringing over 20 years of biotechnology research experience.
Strong financial position with $369.9 million in cash, cash equivalents, and short-term investments, enough to fund operations into mid-2027.
Increased research and development expenses for STAR-0215 and STAR-0310 programs compared to the previous year.
Operating loss increased to $24.2 million for Q1 2024, compared to $13.5 million in Q1 2023.
Net loss also increased to $19.9 million for Q1 2024, compared to $11.2 million in Q1 2023.
Insights
Astria Therapeutics' increased cash position from
However, one cannot overlook the escalation in both R&D and G&A expenses, which have nearly doubled from the prior year. This spike is attributable to the progression of STAR-0215 in international clinical trials and the preparations for the IND submission of STAR-0310. This increase is expected as the company moves into the later stages of clinical development, but it does raise the burn rate and may necessitate further capital in the future, diluting existing shareholders.
An area of concern is the widened operating loss and net loss, growing from
The reported positive proof-of-concept results for STAR-0215 in treating hereditary angioedema (HAE) are promising, showing potential for a significant reduction in attack rates and a good safety profile. Should these results be replicated in Phase 3 trials, STAR-0215 could indeed become a market leader for HAE treatment due to its less frequent dosing schedule (Q3M and potentially Q6M). This convenience factor could greatly improve patient adherence and quality of life, positioning Astria Therapeutics favorably in the market.
However, the road to FDA approval is exhaustive and positive Phase 1b/2 results do not guarantee Phase 3 success. The open-label nature of the upcoming ALPHA-SOLAR trial may bias results positively, which investors should be cautious of when interpreting data. The true test will come with the randomized, controlled Phase 3 trials. If successful, Q3M dosing could be a game-changer, but Q6M dosing will further differentiate STAR-0215 from competitors, offering an even more convenient treatment schedule for patients if it delivers consistent efficacy and safety.
The development of STAR-0310, while only in the preclinical phase, suggests Astria's commitment to expanding its portfolio in the immunological space. The use of YTE technology may enhance the molecule's pharmacokinetics, but the transition from preclinical to clinical stages is fraught with risk and many compounds fail to demonstrate sufficient safety and efficacy in humans.
-- ALPHA-STAR Phase 1b/2 Trial Initial Proof-of-Concept Results Support Potential for STAR-0215 to Become the Market Leader in HAE with Q3M and Q6M Administration --
-- Preclinical Results for STAR-0310, Potential Best-in-Class OX40 Program for the Treatment of Atopic Dermatitis, to be Shared at Upcoming Society for Investigative Dermatology Conference --
“We are thrilled with the ALPHA-STAR initial proof-of-concept results that we shared in March, and believe that STAR-0215 can be a life-changing therapy for people living with HAE,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. “The efficacy we have seen to date, along with the favorable safety and tolerability profile with no injection pain observed, support the ability to administer STAR-0215 every three and every six months and give us confidence that we are developing a therapy that has the potential to lead the HAE market. We are progressing to a pivotal Phase 3 trial, expected to initiate in Q1 2025 for our Q3M regimen. Our plans are to develop a Q3M regimen first to take the fastest path to market, and then to rapidly expand the label with Q6M administration to further reduce the treatment burden for people with HAE.”
STAR-0215
-
The Company shared positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 trial of STAR-0215 in people with hereditary angioedema (HAE) in March 2024. STAR-0215 dosed once or twice over six months reduced monthly attack rates by 90
-96% and supports chronic dosing two or four times per year. The trial saw a 92-100% decrease in moderate or severe attacks and a 91-95% reduction in attacks requiring rescue medications with STAR-0215. Additionally, STAR-0215 was very well-tolerated with no serious adverse events and no discontinuations. Initial pharmacodynamic data show strong, durable, and clinically-relevant inhibition of plasma kallikrein through up to six months after one or two doses. Initial pharmacokinetic data are consistent with modeling developed from the Phase 1a data. The Company plans to report additional data from ALPHA-STAR in the second half of 2024. - Based on the positive results from the ALPHA-STAR trial, Astria plans to advance STAR-0215 to Phase 3 development. To progress STAR-0215 to market as quickly as possible, the Company plans to start the Phase 3 program with Q3M dosing, with trial initiation expected in Q1 2025 and top-line results expected by year-end 2026. The company believes STAR-0215 Q3M dosing will be life-changing for HAE patients, the fastest path to market, and help to establish STAR-0215 as the market leader in HAE. Following the enrollment of the Q3M Phase 3 trial, the Company plans to initiate a Q6M Phase 3 trial to support label expansion with the goal of further solidifying STAR-0215’s leadership position in the HAE market.
- After completion of the ALPHA-STAR trial, patients have the opportunity to continue to receive STAR-0215 every three or six months in the long-term open-label Phase 2 ALPHA-SOLAR trial. Initial safety and efficacy data from ALPHA-SOLAR, including from Q3M and Q6M administration, are expected mid-2025.
STAR-0310
- Astria is developing STAR-0310, a high affinity monoclonal antibody OX40 antagonist that incorporates YTE technology, for the treatment of atopic dermatitis (AD).
- STAR-0310, a preclinical stage program, has the potential to have the best-in-class profile in AD. Astria is on track to submit an Investigational New Drug (IND) application for STAR-0310 by year-end 2024 and plans to initiate a Phase 1a clinical trial in healthy subjects in the first quarter of 2025, with initial results from the trial expected in the third quarter of 2025.
-
Astria will present a poster titled, “Preclinical Profile of STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody” at the Society for Investigative Dermatology (SID) Annual Meeting in
Dallas, Texas . The poster will be available during Session One of the Pharmacology and Therapeutic Development Select E-Poster Discussions on May 16, 2024 at 5:00pm CST.
Corporate Updates
- Astria recently published its inaugural Corporate Social Responsibility (CSR) Report. The 2023 report provides a comprehensive update on the Company’s performance and progress across key Environmental, Social, and Governance (ESG) areas of focus. To learn more about Astria’s CSR initiatives, please view the full report at this link: https://ir.astriatx.com/corporate-social-responsibility.
- Astria appointed Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience.
First Quarter 2024 Financial Results
Cash Position: As of March 31, 2024, Astria had cash, cash equivalents and short-term investments of
R&D Expenses: Research and development expenses were
G&A Expenses: General and administrative expenses were
Operating Loss: Loss from operations was
Net Loss: Net loss was
Net Loss Per Share Basic and Diluted: Net loss per share basic and diluted was
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: our expectations regarding the potential significance of the initial results from the Phase 1b/2 ALPHA-STAR clinical trial of STAR-0215, and that the results from such trial will allow us to move directly into a Phase 3 trial of STAR-0215 as a potential treatment for hereditary angioedema (HAE); the expected timing of the release of additional data from the ALPHA-STAR trial; the expected timing of initiation and design of the planned Phase 3 trials of STAR-0215; the expected timing of release of the safety and efficacy data from the ALPHA-SOLAR trial; the potential for STAR-0215 in the HAE market, including to be the market leader, and to have the best-in-class profile in HAE, the potential therapeutic benefits of STAR-0215 as a treatment for HAE and our vision and goals for the program; the potential for STAR-0310 to have the best-in-class profile in AD and the potential therapeutic benefits and potential attributes of STAR-0310 as a treatment for AD; expectations regarding the timing of regulatory filings for STAR-0310; expectations regarding the timing of initiation and planned design of clinical trials for STAR-0310; the expectations regarding the timing and nature of anticipated data for planned trials of STAR-0310; our goals and vision for STAR-0310; anticipated cash runway; and the goal to meet the unmet needs of patients with rare and niche allergic and immunological diseases. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goals,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or "vision," and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Astria’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, future financial performance, results of pre-clinical and clinical results of the Astria’s product candidates and other future conditions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the following risks and uncertainties: changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies may not be replicated in clinical trials, that the preliminary or interim results from clinical trials may not be indicative of the final results, that the results of early stage clinical trials, such as the results from the Phase 1a clinical trial, may not be replicated in later stage clinical trials, including the ALPHA-STAR trial, the risk that we may not be able to enroll sufficient patients in our clinical trials on a timely basis, and the risk that any of our clinical trials may not commence, continue or be completed on time, or at all; decisions made by, and feedback received from, the
New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Astria may not actually achieve the forecasts or expectations disclosed in our forward-looking statements, and investors and potential investors should not place undue reliance on Astria’s forward-looking statements. Neither Astria, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Astria’s views as of any date subsequent to the date hereof.
Astria Therapeutics, Inc.
Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)
| Three Months Ended March 31, | |||||||||
|
2024 |
|
|
|
2023 |
|
|||
| Operating expenses: | |||||||||
| Research and development | $ |
15,726 |
|
$ |
8,033 |
|
|||
| General and administrative |
|
8,424 |
|
|
5,460 |
|
|||
| Total operating expenses |
|
24,150 |
|
|
13,493 |
|
|||
| Loss from operations |
|
(24,150 |
) |
|
(13,493 |
) |
|||
| Other income (expense): | |||||||||
| Interest and investment income |
|
4,241 |
|
|
2,321 |
|
|||
| Other expense, net |
|
(19 |
) |
|
(16 |
) |
|||
| Total other income, net |
|
4,222 |
|
|
2,305 |
|
|||
| Net loss |
|
(19,928 |
) |
|
(11,188 |
) |
|||
| Net loss per share attributable to common shareholders - basic and diluted | $ |
(0.38 |
) |
$ |
(0.40 |
) |
|||
| Weighted-average common shares outstanding used in net loss per share - basic and diluted |
|
52,294,765 |
|
|
27,944,458 |
|
|||
Astria Therapeutics, Inc.
Selected Consolidated Balance Sheets Data
(In thousands)
(Unaudited)
| March 31, | December 31, | |||||
2024 |
|
2023 |
||||
| Assets | ||||||
| Cash and cash equivalents | $ |
172,012 |
$ |
175,530 |
||
| Short-term investments |
|
197,895 |
|
71,000 |
||
| Right-of-use asset |
|
210 |
|
363 |
||
| Other current and long-term assets |
|
8,690 |
|
7,773 |
||
| Total assets |
|
378,807 |
|
254,666 |
||
| Liabilities and stockholders’ equity | ||||||
| Current portion of operating lease liabilities |
|
168 |
|
329 |
||
| Other current and long-term liabilities |
|
10,904 |
|
11,221 |
||
| Total liabilities |
|
11,072 |
|
11,550 |
||
| Total stockholders’ equity | $ |
367,735 |
$ |
243,116 |
||
Astria Therapeutics, Inc.
Selected Consolidated Statements of Cash Flows Data
(In thousands)
(Unaudited)
| Three Months Ended March 31, | ||||||||
|
2024 |
|
|
|
2023 |
|
||
| Net cash used in operating activities | $ |
(19,094 |
) |
$ |
(13,253 |
) |
||
| Net cash (used in) provided by investing activities |
|
(126,231 |
) |
|
194,992 |
|
||
| Net cash provided by financing activities |
|
141,807 |
|
|
37 |
|
||
| Net (decrease) increase in cash, cash equivalents and restricted cash | $ |
(3,518 |
) |
$ |
181,776 |
|
||
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509444014/en/
Investor Relations and Media:
Elizabeth
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
What are the positive outcomes of the ALPHA-STAR trial for STAR-0215?
What is Astria developing for atopic dermatitis?
Who was appointed to Astria's Board of Directors?
What is Astria's cash position as of March 31, 2024?
What were the net loss figures for the three months ended March 31, 2024?
